Fig. 5

HER2 CAR T cells can effectively treat large, established medulloblastoma xenografts. a Outline of experimental setup. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were given tumor on Day 0 and tumor were allowed to grow until day 22. Mice were treated with 5e6 HER2-BBz CAR T cells or CD19 CAR T cells on Day 22 and tumor growth was monitored by regular BLI imaging for approximately five weeks. Remaining mice were then placed under long-term observation for tumor recurrence. Bioluminescent imaging was performed using a Xenogen IVIS apparatus. b Tumor growth curves for NSG mice with previously described treatments applied on Day 0. Error bars represent standard error of the mean. For statistics, linear regressions were fitted to each curve and slopes were compared using an ANOVA test. c BLI images of mice from each group at selected timepoints. Indicated doses represent number of CAR positive T cells injected per mouse. d Overall survival of mice from each group. HER2 CAR T cell-treated mice were euthanized on Day 37 post-treatment due to animal protocol restrictions, but had no observable tumors (data not shown)